Mirum Pharmaceuticals (MIRM) Capital Expenditures (2019 - 2026)

Mirum Pharmaceuticals' Capital Expenditures history runs 8 years deep, the most recent figure standing at $664000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 1519.51% year-over-year to $664000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 54.46% increase from a year earlier, with the FY2025 full-year figure at $954000.0, down 3.93% from the prior year.
• Capital Expenditures climbed to $664000.0 in Q1 2026 per MIRM's latest filing, from $600000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $779000.0 in Q2 2024 and bottomed at $13000.0 in Q1 2024.
• The 5-year median for Capital Expenditures is $97000.0 (2023), against an average of $214142.9.
• Across the five-year window, Capital Expenditures surged 7966.67% in 2022 and tumbled 83.83% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $242000.0 in 2022, then sank by 71.9% to $68000.0 in 2023, then tumbled by 70.59% to $20000.0 in 2024, then jumped by 2900.0% to $600000.0 in 2025, then advanced by 10.67% to $664000.0 in 2026.
• Per Business Quant, the three latest MIRM Capital Expenditures figures stand at $664000.0 (Q1 2026), $600000.0 (Q4 2025), and $187000.0 (Q3 2025).